Inflammatory reaction plays a key role in the pathogenesis of
hypoxic-ischemic encephalopathy (HIE) in neonates. Microglia are resident innate immune cells in the central nervous system and are profoundly involved in
neuroinflammation. Studies have revealed that
atorvastatin exerts a
neuroprotective effect by regulating
neuroinflammation in adult animal models of brain
stroke and
traumatic brain injury, but its role regarding damage to the developing brain remains unclear. This study aimed to clarify the effect and mechanism of
atorvastatin on the regulation of microglia function in neonatal hypoxic-ischemic brain damage (HIBD). The
oxygen glucose deprivation (OGD) of microglia and neonatal rat HIBD model was established.
Atorvastatin, recombinant sclerostin
protein (SOST), and
XAV939 (degradation of β-
catenin) were administered to OGD microglia and HIBD rats. The pathological changes of brain tissue,
cerebral infarction volume, learning and memory ability of rats, pro-inflammatory (CD16+/Iba1+) and anti-inflammatory (CD206+/Iba1+) microglia markers,
inflammation-related indicators (Inos, Tnfα,
Il6, Arg1, Tgfb, and Mrc1), and Wnt/β-
catenin signaling molecules were examined.
Atorvastatin reduced OGD-induced pro-inflammatory microglia and pro-inflammatory factors, while increasing anti-inflammatory microglia and anti-inflammatory factors. In vivo,
atorvastatin attenuated
hypoxia-
ischemia (HI)-induced
neuroinflammation and brain damage. Mechanistically,
atorvastatin decreased SOST expression and activated the Wnt/β-
catenin signaling pathway, and the administration of recombinant SOST
protein or
XAV939 inhibited Wnt/β-
catenin signaling and attenuated the anti-inflammatory effect of
atorvastatin.
Atorvastatin promotes the pro/anti-inflammatory phenotypic transformation of microglia via the Wnt/β-
catenin pathway in HI neonatal rats.
Atorvastatin may be developed as a potent agent for the treatment of HIE in neonates.